{
    "nctId": "NCT05871125",
    "briefTitle": "Identifying Ideal Reimbursement \"Dose\" to Reduce Clinical Trial-related Financial Toxicity",
    "officialTitle": "Identifying Ideal Reimbursement \"Dose\" to Reduce Clinical Trial-related Financial Toxicity",
    "overallStatus": "ENROLLING_BY_INVITATION",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Number of patients who receive all reimbursements and who complete follow-up surveys (overall feasibility of intervention)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants will be women with breast cancer currently enrolled in the Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and Molecular AnaLysis (I-SPY TRIAL 2) at the UAB Medical Oncology Clinic.\n\nExclusion Criteria:\n\n* Non-English speakers\n* Males\n* Females without cancer\n* Female cancer patients not enrolled in the I-SPY TRIAL 2",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}